Case Report
CDK4/6 inhibitors for primary endocrine resistant HR-positive/HER2-negative metastatic breast cancer: a case report
Translational Breast Cancer Research
2023;
4:
33
(31 October 2023)
Editorial
Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2− metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China
Translational Breast Cancer Research
2023;
4:
32
(31 October 2023)
Editorial
Navigating next-generation HR+/HER2− metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression
Translational Breast Cancer Research
2023;
4:
31
(31 October 2023)
Review Article
Androgen receptor in breast cancer and its clinical implication
Translational Breast Cancer Research
2023;
4:
30
(31 October 2023)
Review Article
A clinical perspective on oncoplastic breast conserving surgery
Translational Breast Cancer Research
2023;
4:
29
(31 October 2023)
Review Article
New-generation technologies for spatial tissue analysis, indispensable tools for deciphering intratumor heterogeneity in the development of antibody-drug conjugates and radio-immunoconjugates for cancer treatment
Translational Breast Cancer Research
2023;
4:
28
(31 October 2023)
Original Article
Self-detection remains a primary means of breast cancer detection in Beijing, China
Translational Breast Cancer Research
2023;
4:
27
(31 October 2023)
Original Article
Interaction of de novo cholesterol biosynthesis and Hippo signaling pathway in ductal carcinoma in situ (DCIS)—comparison with the corresponding normal breast epithelium
Translational Breast Cancer Research
2023;
4:
26
(31 October 2023)
